{
  "ticker": "BOT",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967023",
  "id": "02967023",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250708",
  "time": "0827",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250708/pdf/06lkx61d71dvjg.pdf",
  "summary": "### **Summary of ASX Announcement \u2013 Botanix Pharmaceuticals (ASX: BOT)**  \n\n#### **Sofdra\u2122 Launch Update**  \n- **Gross sales ~AUD $25m** (Jan\u2013Jun 2025)  \n- **2,300+ unique prescribers** in June 2025  \n- **16,000+ prescriptions filled** across 6,700 patients (since launch)  \n- **Refill rates exceed industry average** (3.4 fills vs. 2 for peers)  \n- **GTN yield at 23%** (targeting 30\u201340%)  \n- **Salesforce expansion planned**:  \n  - Current: 33 territories  \n  - Planned: 50 territories by Q2 FY2026  \n\n**No material information omitted.** (Operational metrics indicate strong launch trajectory but no direct capital/trading implications.)  \n\n---  \n*Note: No material capital structure changes, trading halts, or liquidity impacts identified.*",
  "usage": {
    "prompt_tokens": 2435,
    "completion_tokens": 203,
    "total_tokens": 2638,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-07T22:41:44.434672"
}